The management of hepatitis C virus (HCV) infection has evolved quickly since the introduction of direct-acting antiviral agents (DAAs) in 2011. Current treatment options include several DAA combination regimens and each has been associated with achieving sustained virologic response (SVR), or HCV cure. Achieving SVR decreases mortality and reduces a patient’s risk of HCV-related complications, including decompensated cirrhosis and hepatocellular carcinoma. According to current treatment guidelines, achieving SVR is the goal for all patients who receive HCV treatment. While the pace of change in the field of HCV medicine remains rapid and effective, treatment options continue to emerge and challenges remain for clinicians in achieving SVR for all patients. This is particularly true of certain patient populations who have advanced HCV disease, have failed previous HCV treatment, or have concomitant conditions that can complicate treatment such as HIV co-infection or renal insufficiency.
This program will apply emerging evidence and current practice guidelines to address the contemporary challenges in achieving SVR in all patients with HCV, including those who are difficult to treat. Case studies demonstrating new approaches to managing patients with HCV infection will be discussed and the program will emphasize the importance of collaboration among healthcare professionals, including physicians and pharmacists, in order to achieve optimal patient outcomes.